[HTML][HTML] Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A Laupacis, AS Slutsky - Open Medicine, 2010 - ncbi.nlm.nih.gov
Abstract The Canadian Institutes of Health Research and the Multiple Sclerosis (MS) Society
of Canada recently convened an Invitational Panel to consider the scientific evidence linking …

Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public.

A Laupacis, AS Slutsky - Open Medicine: a Peer-reviewed …, 2010 - europepmc.org
Abstract The Canadian Institutes of Health Research and the Multiple Sclerosis (MS) Society
of Canada recently convened an Invitational Panel to consider the scientific evidence linking …

[PDF][PDF] Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A LAUPACIS, A SSlutsky - Open Medicine, 2010 - pdfs.semanticscholar.org
Competing interests: AL is reimbursed by Novartis for his membership on a Data Monitoring
Committee that is monitoring studies of the use of 2 drugs, fingolomid and a drug that has …

[PDF][PDF] Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A LAUPACIS, A SSlutsky - Open Medicine, 2010 - scienceopen.com
Competing interests: AL is reimbursed by Novartis for his membership on a Data Monitoring
Committee that is monitoring studies of the use of 2 drugs, fingolomid and a drug that has …

Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A Laupacis, AS Slutsky - Open medicine: a peer-reviewed …, 2010 - pubmed.ncbi.nlm.nih.gov
The Canadian Institutes of Health Research and the Multiple Sclerosis (MS) Society of
Canada recently convened an Invitational Panel to consider the scientific evidence linking …

[PDF][PDF] Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A LAUPACIS, A SSlutsky - Open Medicine, 2010 - Citeseer
Competing interests: AL is reimbursed by Novartis for his membership on a Data Monitoring
Committee that is monitoring studies of the use of 2 drugs, fingolomid and a drug that has …

[PDF][PDF] Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public

A LAUPACIS, A SSlutsky - Open Medicine, 2010 - academia.edu
Competing interests: AL is reimbursed by Novartis for his membership on a Data Monitoring
Committee that is monitoring studies of the use of 2 drugs, fingolomid and a drug that has …

Endovascular treatment for multiple sclerosis: The intersection of science, policy and the public.

A Laupacis, AS Slutsky - Open Medicine: a Peer-reviewed …, 2010 - europepmc.org
Abstract The Canadian Institutes of Health Research and the Multiple Sclerosis (MS) Society
of Canada recently convened an Invitational Panel to consider the scientific evidence linking …